Kesimpta (Ofatumumab) Pregnancy Registry

RecruitingOBSERVATIONAL
Enrollment

725

Participants

Timeline

Start Date

January 5, 2023

Primary Completion Date

February 28, 2033

Study Completion Date

February 28, 2033

Conditions
Multiple SclerosisPregnancy
Interventions
OTHER

Kesimpta

Prospective non-interventional study. There is no treatment allocation. Patients participating in from the two independent sub-studies, namely the Kesimpta-OTIS sub-study and Kesimpta-DMSKW sub-study, of identical design, conducted in parallel, enrolling pregnant women (MS and non-MS) residing in US or Canada and pregnant women (MS only) from Germany respectively are eligible for enrolling to this study.

Trial Locations (1)

92093-0934

RECRUITING

University of California San Diego OTIS, La Jolla

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY